Literature DB >> 31856540

Near full thickness macular hole with an intact overlying internal limiting membrane following resolution of fulminant acquired toxoplasma retinitis -A unique finding.

Kalpana Babu1, Dhwani Shah1, M Bhagya1, Krishna R Murthy2.   

Abstract

A 43-year-old immunocompetent male presented with focal macular retinitis with overlying vitritis in the right eye. His BCVA was counting fingers close to face. OCT showed increased intraretinal thickness at the area of retinitis with adjacent hypo reflectivity of the choroid. Serology was positive for IgM and IgG antibodies for toxoplasma. He received oral clindamycin 300 mg 4 times/day for 8 weeks. At 6 weeks, his BCVA was CF 2 metres. Fundus showed complete resolution of retinitis with formation of near, full thickness macular hole with intact overlying ILM. A small hyper reflective scar was seen at the base of the macular hole.

Entities:  

Keywords:  Acquired; inner limiting membrane; macular hole; retinitis; toxoplasma

Mesh:

Year:  2020        PMID: 31856540      PMCID: PMC6951158          DOI: 10.4103/ijo.IJO_924_19

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


We report an unusual resolution of acquired, focal, macular, toxoplasma retinitis by destruction of retinal tissue, and formation of a near thickness macular hole with an intact overlying internal limiting membrane (ILM). This is an unusual clinical and OCT finding and has not been described before.

Case Report

A 43-year-old immunocompetent male presented to us with diminution of vision in the right eye of 2 weeks duration. On examination, his BCVA was counting fingers (CF) close to face in the right eye and 20/20 in the left eye. Fundus examination of the right eye showed focal macular retinitis with overlying vitritis [Fig. 1a]. Optical coherence tomography (OCT) showed increased intraretinal thickness at the area of retinitis with corresponding underlying hypo reflectivity of the choroid possibly due to shadowing effect [Fig. 1b]. Left eye examination was normal. Intraocular pressures were in the normal. Range. Enzyme linked immunosorbent assay (ELISA) was positive for IgM and IgG (210 IU/L) antibodies for toxoplasmosis confirming the diagnosis of acquired toxoplasma retinitis in the right eye. Other laboratory investigations including complete haemogram, venereal disease research laboratory (VDRL), treponemal pallidum haemagglutination test (TPHA), Weil-felix test, ELISA for HIV, mantoux test, random blood sugar, urine routine, and chest X-ray were noncontributory.
Figure 1

Fundus photograph of the right eye at presentation showing macular retinitis (a). Spectral OCT shows increased intraretinal thickness at the area of retinitis with corresponding underlying hypo reflectivity of the choroid (b)

Fundus photograph of the right eye at presentation showing macular retinitis (a). Spectral OCT shows increased intraretinal thickness at the area of retinitis with corresponding underlying hypo reflectivity of the choroid (b) Treatment included oral clindamycin 300 mg, qid for 8 weeks. Oral steroids were started 3 days after starting clindamycin and tapered by 10 mg/week over 4 weeks. At 3 weeks, his BCVA had improved to CF 2 meters. Fundus examination showed near complete resolution of retinitis with formation of near full thickness macular hole. [Fig. 2a] OCT confirmed loss of macular tissue with intact overlying ILM akin to a “bridge sign”. A small hyperreflective scar was seen at the base and edema noted at the margins of the macular hole. [Fig. 2b] At 8 weeks there was complete resolution of retinitis with loss of intraretinal tissue with intact overlying ILM. [Fig. 3a and b] At 6 months, his BCVA remained stable at CF 2 meters with complete loss of intraretinal tissue with overlying intact ILM or the bridge sign on the OCT [Fig. 3c and d].
Figure 2

Fundus photograph of the right eye at the end of 3 weeks showing near complete resolution of retinitis with total loss of intraretinal tissue (a) and an intact overlying ILM or bridge sign on spectral OCT (b). Also seen is edema along the margins of the macular hole and a hyperreflective scar at the base of the macular hole

Figure 3

Fundus photograph of the right eye at 8 weeks (a) and 6 months (b) showing total loss of intraretinal tissue with complete resolution of retinitis with an overlying intact ILM—the bridge sign at 8 weeks (c) and at 6 months (d) on spectral OCT

Fundus photograph of the right eye at the end of 3 weeks showing near complete resolution of retinitis with total loss of intraretinal tissue (a) and an intact overlying ILM or bridge sign on spectral OCT (b). Also seen is edema along the margins of the macular hole and a hyperreflective scar at the base of the macular hole Fundus photograph of the right eye at 8 weeks (a) and 6 months (b) showing total loss of intraretinal tissue with complete resolution of retinitis with an overlying intact ILM—the bridge sign at 8 weeks (c) and at 6 months (d) on spectral OCT

Discussion

Macular hole following toxoplasma retinitis secondary to vitreous traction have been described.[123] Macular infarction has been described in toxoplasma retinochoroiditis.[4] In this case, we speculate that the retinitis was fulminant and had caused destruction of the macular tissue resulting in a near full thickness macular hole. This unusual pattern of resolution of retinitis with sparing of the overlying ILM, resulted in a “bridge sign” on the OCT. This “bridge sign” pattern on OCT has been described in idiopathic parafoveal telangiectasia.[5] A small scar was also seen at the base of the macular hole in our case on OCT.

Conclusion

Unusual pattern of resolution of retinitis with the characteristic finding of “bridge sign” on OCT is unique and has not been described before in toxoplasma retinitis.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography.

Authors:  Lelia A Paunescu; Tony H Ko; Jay S Duker; Annie Chan; Wolfgang Drexler; Joel S Schuman; James G Fujimoto
Journal:  Ophthalmology       Date:  2005-12-15       Impact factor: 12.079

2.  Macular infarction in a patient with Toxoplasma retinochoroditis.

Authors:  Vinod Kumar; Brijesh Takkar; Parijat Chandra; Atul Kumar
Journal:  BMJ Case Rep       Date:  2016-01-11

3.  Macular hole secondary to toxoplasmic retinochoroiditis.

Authors:  Begoña Arana; Alex Fonollosa; Joseba Artaraz; Agustin Martinez-Berriotxoa; Nerea Martinez-Alday
Journal:  Int Ophthalmol       Date:  2013-03-12       Impact factor: 2.031

4.  Macular hole formation after toxoplasmic retinochoroiditis.

Authors:  Georgios D Panos; Elena Papageorgiou; Nikolaos Kozeis; Zisis Gatzioufas
Journal:  BMJ Case Rep       Date:  2013-03-06

5.  Vitreoretinal traction and lamellar macular holes associated with cicatricial toxoplasmic retinochoroiditis: case series report.

Authors:  Alvaro Rodríguez; Marcela Valencia; Flor E Gomez
Journal:  Eur J Ophthalmol       Date:  2016-08-04       Impact factor: 2.597

  5 in total
  2 in total

1.  Commentary: Internal limiting membrane sparing in necrotizing focal retinitis.

Authors:  Mohit Dogra; Simar Rajan Singh
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

2.  Sequential multimodal imaging of isolated necrotic full-thickness macular hole secondary to toxoplasma retinochoroiditis.

Authors:  Shreyas Shah; George J Manayath; Ratnesh Ranjan; Narendran Venkatapathy; Anuradha Kanakath
Journal:  Am J Ophthalmol Case Rep       Date:  2021-08-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.